{"title":"乌云笼罩着日本的再生医学。","authors":"Hiroshi Kawaguchi","doi":"10.1089/scd.2025.0012","DOIUrl":null,"url":null,"abstract":"<p><p>Japan's regenerative medicine sector has encountered major challenges, underscored by the recent failures of products such as HeartSheet and Collategene. These setbacks expose critical weaknesses in the fast-track approval system, raising concerns about patient safety and the scientific robustness of product evaluations. Despite strong governmental support, addressing these fundamental issues is essential for the future success of regenerative medicine in Japan.</p>","PeriodicalId":94214,"journal":{"name":"Stem cells and development","volume":" ","pages":"149-151"},"PeriodicalIF":2.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dark Clouds Looming Over Regenerative Medicine in Japan.\",\"authors\":\"Hiroshi Kawaguchi\",\"doi\":\"10.1089/scd.2025.0012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Japan's regenerative medicine sector has encountered major challenges, underscored by the recent failures of products such as HeartSheet and Collategene. These setbacks expose critical weaknesses in the fast-track approval system, raising concerns about patient safety and the scientific robustness of product evaluations. Despite strong governmental support, addressing these fundamental issues is essential for the future success of regenerative medicine in Japan.</p>\",\"PeriodicalId\":94214,\"journal\":{\"name\":\"Stem cells and development\",\"volume\":\" \",\"pages\":\"149-151\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Stem cells and development\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1089/scd.2025.0012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem cells and development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/scd.2025.0012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Dark Clouds Looming Over Regenerative Medicine in Japan.
Japan's regenerative medicine sector has encountered major challenges, underscored by the recent failures of products such as HeartSheet and Collategene. These setbacks expose critical weaknesses in the fast-track approval system, raising concerns about patient safety and the scientific robustness of product evaluations. Despite strong governmental support, addressing these fundamental issues is essential for the future success of regenerative medicine in Japan.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
